GRAL · GRAIL, Inc.
$138.14
-1.98 (-1.41%)
At close · Oct 1
Return incl. dividend (before tax)
Market Cap
$5.67B
Shares
44.67M
Volume · Oct 1
215.96K
Avg daily vol (3M)
884.02K
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$140.12
Open$138.27
Day$136.00–151.46
52W close$43.03–140.12
Avg vol 30d1.2M
Short int8.6M · 19.2% float · 12.7d
Short vol62%
Last earningsAug 5, 2026
DataJun 2024–Sep 2026
Filing10-Q · Aug 6
Up next
Next earnings call
Oct 28, 2026
Est · unconfirmed
· in 4 wks
filed Aug 6, 2026
call held Aug 5, 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
$165.26M
Trailing 12 months
Net income (TTM)
−$391.59M
Trailing 12 months
Revenue growth YoY
+25.7%
Year over year
Operating margin
-338.4%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
-5.2%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$55.65M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+20.4%
Year over year · more shares
Price change (1Y)
+132.4%
Trailing year
Short interest
19.2%
Latest settlement · 12.7 days to cover
Equibles Rating
blended score · not investment adviceOverall
Buy
SellHoldBuy
Technical
Buy
Momentum
Very Strong
Sentiment
Neutral
Fundamentals
Strong
Quant / Vol
Very High
Market backdrop
VIX 16.3 · calm
Equity put/call 0.53
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+92%
above
Price vs 50-day avg
+72%
above
RSI (14)
90
overbought
MACD trend
Positive
52-week position
100%
near high
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
+77%
trailing
6-month return
+176%
trailing
YTD return
+64%
this year
Relative strength
+164%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $81 › 200d $73 — 50d above 200d
Institutional flow
Accumulating
+2% holders QoQ · +64 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
19.18% of float · ▲ +0.6% MoM · 12.7 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
380 holders — mid 2-yr range
Squeeze score
95
high risk · 0–100
Fundamentals
Revenue growth
+17%
Y/Y
EPS growth
+83%
Y/Y
Free cash flow
$-299.9M
Quant / Vol
risk profile
Volatility
104%
annualized · 1-yr
Max drawdown
−63%
past year
ATR
6.1%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the Earnings Call filed Mar 31, 2026
Revenue growth
· the year
22% – 32%
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Buy
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+92%
Bullish
Price vs 50-day avg
+72%
Bullish
RSI (14)
90
Bearish
MACD trend
Positive
Bullish
52-week position
100%
Bullish
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Mixed
Trend (MA cross)
No cross
50d $81 › 200d $73 — 50d above 200d
Institutional flow
Accumulating
+2% holders QoQ · +64 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
19.18% of float · ▲ +0.6% MoM · 12.7 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
380 holders — mid 2-yr range
Price context
position in its 52-week range
Range low $43
Now $140 · 100%
Range high $140
vs 200-day avg +92%
vs 50-day avg +72%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
Versus peers
Diagnostics & Research — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
GRAL
this stock
GRAIL, Inc.
|
$5.67B | +63.7% | +17.2% | — | 19.2% |
|
TMO
Thermo Fisher Scientific Inc.
|
$249.58B | +16.5% | +14.5% | 36.3 | 1.4% |
|
DHR
Danaher Corp /De/
|
$155.42B | -3.2% | +8.5% | 39.2 | 1.2% |
|
NTRA
Natera, Inc.
|
$59.47B | +80.4% | -2.8% | — | 3.3% |
|
A
Agilent Technologies, Inc.
|
$48.90B | +26.6% | +6.4% | 34.2 | 1.8% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| GRAL | +29.1% | +76.5% | +175.9% | +76.5% | +63.7% |
| SPY | -0.7% | +0.1% | +12.2% | -0.6% | +11.8% |
| vs SPY | +29.8% | +76.4% | +163.8% | +77.1% | +51.9% |
Key facts
CIK
1699031
CUSIP
384747101
13F (30d)
14 filings
13 filers
Visit website
Investor relations